United States Patent 6,455,574 (amlodipine + atorvastatin combination): Scope, Claim Boundaries, and Landscape
What does US 6,455,574 claim, in force-sensitive terms?
US 6,455,574 claims a specific combined drug-regimen method for treating a mammal with combined hypertension and hyperlipidemia using two named actives:
- First compound (A): amlodipine (or a pharmaceutically acceptable acid addition salt)
- Second compound (B): atorvastatin (or a pharmaceutically acceptable salt)
- Key regimen constraint: A and B are administered together in a single pharmaceutical composition with a pharmaceutically acceptable carrier or diluent
The claims are method-of-treatment claims. They do not claim a new chemical entity; they claim the treatment method and the single-composition joint administration.
Claim set (independent and dependent)
- Claim 1 (independent): Method for treating a mammal suffering from combined hypertension and hyperlipidemia using
(a) amlodipine (or acid addition salt) and
(b) atorvastatin (or salt)
with both administered together in one pharmaceutical composition.
- Claims 2-4 (dependent): Restrict salts and salt identity:
- Claim 2: amlodipine besylate
- Claims 3 and 4: atorvastatin hemicalcium salt
- Claims 5-12 (independent-style but still method claims with additional diagnosis/risk framing and prescription framing):
- Claim 5: Diagnosed (and prescribed) mammal with hypertension and hyperlipidemia or risk thereof; joint administration in a single pharmaceutical composition
- Claims 6-8: amlodipine besylate and atorvastatin hemicalcium salt restrictions
- Claims 9-12: Mammal examined/diagnosed by medical practitioner and in need of therapy via joint administration; joint administration in a single pharmaceutical composition, plus salt restrictions
Structural claim boundary that drives infringement and non-infringement
The core narrowing element repeated throughout is:
“wherein said first compound and said second compound are administered together in a single pharmaceutical composition”
This is the central scope limiter. Any design-around that separates dosing into two dosage forms (even if taken concurrently) targets this limitation.
What exactly are the chemical/salt scopes?
The patent uses a two-tier approach: broad genus claim language in independent claims, then salt-specific dependent claims.
A. Amlodipine scope (Claim 1 genus → Claim 2 exact salt)
- Claim 1: amlodipine or pharmaceutically acceptable acid addition salt
- Claim 2: amlodipine besylate
So the patent’s claim 1 covers amlodipine generally and multiple acid-addition salts. The salt identity is fixed only in the dependent claims.
B. Atorvastatin scope (Claim 1 genus → Claims 3/4/7/8/11/12 exact salt)
- Claim 1: atorvastatin or pharmaceutically acceptable salt
- Claims 3 and 4: hemicalcium salt of atorvastatin
- Claims 7/8/11/12: same restriction in the corresponding claim sets
So hemicalcium atorvastatin is a particular claim target. Genus coverage in claim 1 is broader, but always tied to single-composition co-administration.
How broad is the “combined hypertension and hyperlipidemia” requirement?
All claims require that the treated mammal has:
- combined hypertension and hyperlipidemia, or
- risk of both (Claim 5 language), or
- has been diagnosed and prescribed therapy for both (Claim 5 framing; Claims 9-12 include physician examination/diagnosis language).
This creates a factual and labeling/medical-record component for enforcement:
- It is not “either hypertension or hyperlipidemia.”
- It is “both conditions together” (or both risk elements) as the target condition for therapy.
What does “single pharmaceutical composition” mean in practice?
Across Claims 1, 5, and 9 (the repeating independent structures), infringement hinges on whether A and B are in the same composition (same formulation / single dosage form), not just taken at the same time.
That language typically maps to:
- a fixed-dose combination product (single tablet, capsule, or unit dosage containing both actives), or
- a composition where both drugs are co-formulated in one dosage unit.
It is not written as “co-administered” generally; it is written as “administered together in a single pharmaceutical composition.”
Claim-by-claim scope mapping
Below is the operational scope for the claims you provided.
| Claim |
Treatment target framing |
First active (A) |
Second active (B) |
Co-administration constraint |
| 1 |
combined hypertension + hyperlipidemia |
amlodipine or acid addition salt |
atorvastatin or salt |
single pharmaceutical composition |
| 2 |
Claim 1 + salt |
amlodipine besylate |
atorvastatin or salt |
single pharmaceutical composition |
| 3 |
Claim 1 + salt |
amlodipine (or acid-addition salt) |
hemicalcium atorvastatin |
single pharmaceutical composition |
| 4 |
Claim 1 + salt |
amlodipine (or acid-addition salt) |
hemicalcium atorvastatin |
single pharmaceutical composition |
| 5 |
diagnosed (or risk) + prescribed |
amlodipine or acid addition salt |
atorvastatin or salt |
single pharmaceutical composition |
| 6 |
Claim 5 + salt |
amlodipine besylate |
atorvastatin or salt |
single pharmaceutical composition |
| 7 |
Claim 5 + salt |
amlodipine besylate |
hemicalcium atorvastatin |
single pharmaceutical composition |
| 8 |
Claim 5 + salt |
amlodipine or besylate (per dependency text you provided) |
hemicalcium atorvastatin |
single pharmaceutical composition |
| 9 |
examined/diagnosed + in need + joint administration |
amlodipine or acid addition salt |
atorvastatin or salt |
single pharmaceutical composition |
| 10 |
Claim 9 + salt |
amlodipine besylate |
atorvastatin or salt |
single pharmaceutical composition |
| 11 |
Claim 9 + salt |
amlodipine besylate |
hemicalcium atorvastatin |
single pharmaceutical composition |
| 12 |
Claim 9 + salt |
amlodipine or besylate (per dependency text you provided) |
hemicalcium atorvastatin |
single pharmaceutical composition |
What is the likely patent landscape logic around this combination?
US 6,455,574 sits in a landscape where major barriers are rarely “new drug discovery” and more often:
- Combination product scope (fixed-dose co-formulations)
- Salt/formulation selections (specific salt forms)
- Method-of-use claim strategy tied to a clinical indication (“combined hypertension + hyperlipidemia”)
Landscape pressure points that matter for enforcement/infringement
1) If a product uses separate dosage forms
Because the claims require a single pharmaceutical composition, a product that provides:
- amlodipine in one dosage form and
- atorvastatin in a separate dosage form
even when prescribed together, becomes a direct attack line against literal infringement of the “single composition” limitation.
2) If a product uses a different statin or different antihypertensive
The claims are tightly tethered to:
- amlodipine (or acid-addition salts)
- atorvastatin (or salts)
A product substituting rosuvastatin, simvastatin, or another CCB/ACE/ARB avoids the actives requirement.
3) Salt form strategy
The genus claims include salt forms broadly, but the patent explicitly narrows to:
- amlodipine besylate
- atorvastatin hemicalcium
If a competitor uses other acceptable salts, they may still fall within the genus unless the competitor’s formulation falls outside what is treated as “pharmaceutically acceptable salt” in the claim construction, but the dependent claims specifically target these exact salts.
Practical effect on “freedom to operate” type decisions
From a risk-management view, this patent is most relevant when a company is:
- developing or marketing a fixed-dose combination containing both amlodipine and atorvastatin in one unit dosage, and
- aiming the product at patients with both hypertension and hyperlipidemia (or risk of both), and
- using amlodipine salts and atorvastatin salts that can be argued to land within the claim scope.
What are the claim patterns that increase resilience against narrow attacks?
Even though the actives and formulation constraint narrow scope, the patent increases coverage resilience via redundant independent structures:
- Claim 1 is broad on the “combined condition” treatment.
- Claim 5 adds prescription/diagnosis framing (“diagnosed… and prescribed…”).
- Claim 9 adds a physician examination/diagnosis narrative and in-need for joint administration.
All retain the “single pharmaceutical composition” limitation and the same core actives. This reduces the likelihood that a narrow factual framing defense completely neutralizes the claim set.
What is the practical scope that an innovator would advertise?
To align with these claims, an asserted product would typically involve:
- a fixed-dose combination (single tablet/capsule)
- patient indication/labeling centered on both hypertension and hyperlipidemia
- co-administration in one dosage unit containing amlodipine and atorvastatin
Key takeaways for business decisions
- The patent is a method-of-treatment claim centered on fixed-dose co-formulation: amlodipine + atorvastatin in one pharmaceutical composition for patients with combined hypertension and hyperlipidemia (or risk).
- The decisive infringement lever is the “single pharmaceutical composition” requirement.
- Salt selection matters: dependent claims lock in amlodipine besylate and atorvastatin hemicalcium, while independent claims cover broader salt genera.
- Landscape relevance concentrates on competitors marketing a fixed-dose combination (not separate tablets taken concurrently) using the same two actives for the combined condition.
Key Takeaways
- US 6,455,574 claims joint treatment using amlodipine + atorvastatin in a single pharmaceutical composition for combined hypertension and hyperlipidemia.
- Single-composition co-formulation is the core scope limiter; dosing in separate products is the primary non-infringement design axis.
- Dependent claims narrow to amlodipine besylate and atorvastatin hemicalcium, while independent claims cover broader salt genera.
- The claim set uses multiple method claim framings (diagnosed/prescribed; examined/diagnosed) without changing the actives and single-composition requirement.
FAQs
-
Does the patent claim a new drug compound?
No. It claims a method of treating with existing actives (amlodipine and atorvastatin) and a single-composition joint administration.
-
What is the hardest-to-avoid claim element?
The requirement that the actives are administered together in a single pharmaceutical composition.
-
Do dependent claims matter for product planning?
Yes. They specify amlodipine besylate and atorvastatin hemicalcium, narrowing target salt forms.
-
Can a competitor avoid infringement by prescribing both drugs separately?
The claims are written to require a single pharmaceutical composition, so separate dosage forms create a direct tension with literal claim scope.
-
Is “risk” of disease covered?
Yes. Claim 5 includes patients with risk of hypertension and hyperlipidemia who would benefit from combined therapy.
References
[1] United States Patent No. 6,455,574.
